You have no items in your shopping cart.
Search results for: 'SARS-CoV-2'
98.00%
133.96 kDa (predicted)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike S1+S2 (YP_009724390.1, with mutations Q52R, A67V, HV69-70 deletion, Y144 deletion, E484K, D614G, Q677H, F888L) (Met1-Pro1213) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.525) which emerged in the Multiple countries. Predicted N terminal: Val 16
C-His
100 μg98.00%
136.29 kDa (predicted)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike S1+S2 (YP_009724390.1, with mutations G142D, E154K, L452R, E484Q, D614G, P681R, Q1071H, H1101D) (Met1-Pro1213) was expressed with a C-terminal polyhistidine tag followed by an AVI tag. The expressed protein was biotinylated in vivo by the Biotin-Protein ligase (BirA enzyme) which is co-expressed. The mutations were identified in the SARS-CoV-2 variant (known as B.1.617) which emerged in the India. Predicted N terminal: Val 16
C-His-Avi
20 μg98.00%
135.90 kDa (predicted)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike S1+S2 (YP_009724390.1, with mutations (HV69-70,Y145)deletion, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H) (Met1-Pro1213) was expressed with a C-terminal polyhistidine tag followed by an AVI tag. The expressed protein was biotinylated in vivo by the Biotin-Protein ligase (BirA enzyme) which is co-expressed. The mutations were identified in the SARS-CoV-2 variant (known as B.1.1.7) which emerged in the UK. Predicted N terminal: Val 16
C-His-Avi
20 μg98.00%
76.17 kDa (predicted); 101.09 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike S1 (YP_009724390.1, with mutations G75V, T76I, R246N, 247 deletion, 253 deletion, L452Q, F490S, D614G) (Met1-Arg685) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant C.37) which emerged in the Peru. Predicted N terminal: Val 16
C-His
100 μg98.00%
26.83 kDa (predicted); 34.86 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutation G339D, S371L, S373P, S375F, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H) (Arg319-Phe541) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.1.529) which emerged in the South Africa. Predicted N terminal: Arg 319
C-His
100 μg98.00%
51.78 kDa (predicted); 56.20 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutation G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H) (Arg319-Phe541the Fc region of mouse IgG1 at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.1.529) which emerged in the South Africa. Predicted N terminal: Arg 319
C-mFc
100 μg98.00%
138.07 kDa (predicted)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 (BA.4/BA.5/BA.5.2) Spike S1+S2 trimer (YP_009724390.1, with mutations T19I, L24del, P25del, P26del, A27S, H69del, V70del, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, F817P, A892P, A899P, A942P, Q954H, N969K, K986P, V987P and furin cleavage site mutants) (Met1-1208Q) was expressed with bacteriophage T4 fibritin and a C-terminal polyhistidine tag followed by an AVI tag. The mutations were identified in the SARS-CoV-2 variant (known as variant BA.4/BA.5/BA.5.2).The expressed protein was biotinylated in vivo by the Biotin-Protein ligase (BirA enzyme) which is co-expressed. Predicted N terminal: Val 16
C-His-Avi
20 μg98.00%
28.53 kDa (predicted); 37.23 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutation G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452Q, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H) (Arg319-Phe541) was expressed with a C-terminal polyhistidine tag followed by an AVI tag. The expressed protein was biotinylated in vivo by the Biotin-Protein ligase (BirA enzyme) which is co-expressed. The mutations were identified in the SARS-CoV-2 variant (known as variant BA.2.12.1). Predicted N terminal: Arg 319
C-His-Avi
20 μg98.00%
33.68 kDa (predicted); 54.37 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike S1-NTD (YP_009724390.1, with mutations A67V, H69del, V70del, T95I, G142D, V143del, Y144del, Y145del, N211del, L212I) (Met1-Ser305) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.1.529) which emerged in the South Africa. Predicted N terminal: Val 16
C-His
100 μg98.00%
136.41 kDa (predicted)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 (BA.2.75.2) Spike S1+S2 (YP_009724390.1, with mutations T19I, L24S, del25-27, G142D, K147E, W152R, F157L, I210V, V213G, G257S, G339H, R346T, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, G446S, N460K, S477N, T478K, E484A, F486S, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, F817P, A892P, A899P, A942P, Q954H, N969K, K986P, V987P, D1199N and furin cleavage site mutants) expressed with the bacteriophage T4 fibritin and a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant BA.2.75.2). Predicted N terminal: Val 16
C-His
100 μg
